Cogent Biosciences Inc Investor Relations Material
Latest events
Study Update
Cogent Biosciences Inc
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cogent Biosciences Inc
Access all reports
Cogent Biosciences Inc. is a biotechnology company focused on the development of precision therapies for genetically defined diseases. The company's lead product, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor targeting mutations in the KIT receptor tyrosine kinase. These mutations are critical in conditions such as systemic mastocytosis and advanced gastrointestinal stromal tumors. Cogent Biosciences holds a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Cogent Biosciences Inc
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024
Cogent Biosciences Inc
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024
Cogent Biosciences Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
COGT
Country
🇺🇸 United States